医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Syncell Welcomes New Management Team Members, Philippe Lyko and Nikhil Rao

2024年08月09日 PM06:38
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan & WATERTOWN, Mass.

Syncell, a leader in next-generation spatial proteomics, is pleased to announce the addition of Philippe C. Lyko as Chief Financial Officer (CFO) and Nikhil Rao, PhD, as Senior Vice President of Commercial. These appointments strengthen Syncell’s leadership team as the company enters a pivotal phase of growth and commercial expansion.

Philippe Lyko joins Syncell following a successful tenure at DNA Script, a pioneer in Enzymatic DNA Synthesis technology, where he held the reins as CFO for three years. Lyko brings a wealth of financial expertise, accumulated over 27 years across various industries, including significant roles in the life sciences sector. His experience also includes critical financial leadership positions at Helix, Illumina, and Flexport, where he played a key role in scaling finance operations during periods of rapid growth. Lyko’s diverse background and strategic financial acumen make him a valuable addition to Syncell as it launches the Microscoop® platform, aiming to revolutionize proteomic discovery.

Nikhil Rao, PhD, joins Syncell as Senior Vice President of Commercial. Rao brings a distinguished career in the life sciences, particularly in the areas of spatial biology and multiomics. He most recently served as Vice President of the Spatial Business Unit at 10x Genomics, where he was instrumental in launching the Visium and Xenium platforms, significantly driving the company’s revenue. His expertise in product management and market strategy will be crucial as Syncell expands its innovative offerings in spatial proteomics. Rao holds a PhD in Bioengineering from UC San Diego and a B.S. in Chemical & Biomolecular Engineering from The Johns Hopkins University.

“We are thrilled to welcome Philippe and Nikhil to the Syncell team,” said Jung-Chi Liao, founder and CEO of Syncell. “Their extensive experience and leadership will be invaluable as we accelerate our mission to advance proteomic technologies and drive the commercial success of our groundbreaking Microscoop® platform.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808718010/en/

CONTACT

For more information, please contact Syncell at info@syncell.com.

同じカテゴリーの記事 

  • オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®(タピナロフ)クリーム1%を取得
  • Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
  • Weave Named a Great Place to Work in the U.S. and India
  • Organon将收购Dermavant,包括其创新皮肤疗法VTAMA® (tapinarof) 1%乳膏
  • Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024